Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Lifestyle Care Plan for Long-Term Lymphoma Survivors

Tests a healthy lifestyle care plan in adults surviving lymphoma in remission.

Plain-language title generated from the registry record
Registry title: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Key facts

Where
Ancona, Aviano, Bari, Barletta, Belluno, Bolzano, Brescia, Brindisi, Caltanissetta, Catania, Como, Florence, Lecce, Legnano, Messina, Milan, Modena, Novara, Padova, Pagani, Palermo, Pescara, Piacenza, Pisa, Potenza, Reggio Emilia, Rimini, Roma, Rozzano, Sassari, Sassuolo, Torino, and Treviso, ItalySee the 40 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

Source: NCT05934084, who can take part

Where in Italy

  • Ancona - AOU Ospedali Riuniti - Clinica di EmatologiaAncona, ItalyTaking people
  • Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlatiAviano, ItalyTaking people
  • Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia CellulareBari, ItalyTaking people
  • Ospedale "Monsignor Raffaele Dimiccoli" - EmatologiaBarletta, ItalyTaking people
  • Ospedale S. Martino - UOC OncologiaBelluno, ItalyTaking people
  • Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.Bolzano, ItalyTaking people
  • ASST Spedali Civili di Brescia, EmatologiaBrescia, ItalyTaking people
  • Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di MidolloBrindisi, ItalyTaking people
  • PO Sant'Elia ASP Caltanisetta - UOC EmatologiaCaltanissetta, ItalyNot yet recruiting
  • Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. EmatologiaCatania, ItalyTaking people
  • Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di EmtologiaCatania, ItalyTaking people
  • Ospedale Generale di zona Valduce - OncoematologiaComo, ItalyTaking people
  • Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di EmatologiaFlorence, ItalyTaking people
  • Ospedale Vito Fazzi - EmatologiaLecce, ItalyTaking people
  • ASST Ovest Milanese - Legnano - U.O.C. Ematologia Ospedale Civile di LegnanoLegnano, ItalyTaking people
  • AOU G. Martino - U.O.C. EmatologiaMessina, ItalyNot yet recruiting
  • ASST Grande Ospedale Metropolitano Niguarda - SC EmatologiaMilan, ItalyTaking people
  • IEO Istitito Europeo di Oncologia - Divisione EmatoncologiaMilan, ItalyTaking people
  • Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - EmatologiaMilan, ItalyTaking people
  • Azienda Ospedaliero-Universitaria Policlinico di Modena - U.O. OncologiaModena, ItalyTaking people
  • AOU Maggiore della Caritа di Novara, SCDU EmatologiaNovara, ItalyTaking people
  • AOU di Padova - EmatologiaPadova, ItalyTaking people
  • I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1Padova, ItalyTaking people
  • Presidio ospedaliero A. Tortora, U.O. Onco-ematologiaPagani, ItalyTaking people
  • AOU Policlinico Giaccone - EmatologiaPalermo, ItalyTaking people
  • P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomiPescara, ItalyTaking people
  • Ospedale Guglielmo da Saliceto - U.O. EmatologiaPiacenza, ItalyTaking people
  • AOU G. Martino - U.O.C. EmatologiaPisa, ItalyNot yet recruiting
  • A.O.R. "San Carlo" - U.O. EmatologiaPotenza, ItalyNot yet recruiting
  • Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - EmatologiaReggio Emilia, ItalyTaking people
  • Ospedale degli Infermi di Rimini - U.O. di EmatologiaRimini, ItalyTaking people
  • AO Sant'Andrea - EmatologiaRoma, ItalyTaking people
  • Ospedale S. Eugenio - UOC EmatologiaRoma, ItalyTaking people
  • Policlinico Tor Vergata - EmatologiaRoma, ItalyNot yet recruiting
  • Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulareRoma, ItalyTaking people
  • Istituto Clinico Humanitas - U.O. EmatologiaRozzano, ItalyNo longer taking part
  • AOU di Sassari - EmatologiaSassari, ItalyTaking people
  • Nuovo Ospedale Civile di Sassuolo - Day Hospital OncologicoSassuolo, ItalyTaking people
  • A.O.U. Città della Salute e della Scienza di Torino, Ematologia UniversitariaTorino, ItalyTaking people
  • Ospedale Ca Foncello - S.C di EmatologiaTreviso, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Fondazione Italiana Linfomi - ETS
Trial code
NCT05934084
Record updated
11 September 2026
Original description
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).Read full original descriptionShow less

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors: A Randomized Non-pharmacological Clinical Trial By The Fondazione Italiana Linfomi (FIL)

This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).

Inclusion: Age 18-50 at initial treatment; Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL) or Primary mediastinal large B-cell lymphoma (PMBCL); Patients in Complete Remission (CR) after first-line therapy [ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin , cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2 guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adapted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL); Patients in remission for a minimum 3 years since the last treatment and a maximum of 10 years; Cumulative doxorubicin/ adriamycin dose received of at least 200 mg/mq (4 cycles of chemotherapy); Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensional speckle strain echocardiography) performed no later than three months prior to enrollment; Signature of a written informed consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate voluntarily in the study.

Exclusion: Second line chemotherapy of stem cell transplant; Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers and adequately treated cone-biopsied in situ carcinoma of the cervix; Cardiovascular disease: arrhythmia >/= grade 2, hypertension >/ grade 2, left ventricular dysfunction >/= grade 2 pericardial disease/effusion any grade, myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathy any grade valvular hearth disease >/= grade 2, right ventricular dysfunction >/= grade 2; Venous thromboembolism or arterial thrombosis during last 6 months; Hemorrhage/ bleeding >/= grade 2 during last 6 months; Rheumatic disease or inflammatory bowel disease in systemic treatment; Not able to perform physical activity; Grade >/=3 neuropathy; Vertebral fractures or stenosis of the vertebral canal; other bone fracture; Chronic lymphedema (arms and/ or limbs); Any pleural effusion; If female, the patient is pregnant; Unwilling to comply to all required visits and procedures for the duration of study participation.

ClinicalTrials.gov NCT05934084